The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
Abstract
Toxicity of 6‐hydroxydopamine (6‐OHDA) and dopamine were studied in cultures of dissociated fetal rat mesencephalic cells. To assess survival and function of dopaminergic cells we quantified the number of tyrosine hydroxylase‐positive cells and measured dopamine uptake. Non‐dopaminergic cells were monitored by counting the number of cells visible with phase‐contrast microscopy and measuring GABA uptake. 6‐OHDA, in contrast to MPP +, which selectively destroyed dopaminergic neurons, was found to be a non‐selective neurotoxin in this culture system. Between 10 and 100 μM, dopaminergic and non‐dopaminergic cells were destroyed. At concentrations frequently used to lesion catecholaminergic neurons in vivo, 6‐OHDA resulted in structural fixation and loss of viability of dopaminergic and non‐dopaminergic cells. Dopamine produced the same actions at slightly higher concentrations. One hundred to 300 μM was toxic for all cell types, and concentrations above 300 μM resulted in fixation. The findings suggest that 6‐OHDA cannot be considered a selective toxin for catecholaminergic neurons in vitro. The demonstrated toxicity of dopamine tends to support speculations that processes related to dopamine metabolism may play a role in the pathogenesis of Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Chiba, K., Trevor, A., & Castagnoli, N. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91293-2 · Cited by 1,097
Cohen, G., Heikkila, R. E., & MacNamee, W. T. T. A. O. D. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42751-8 · Cited by 897
Pharmacological Actions of 6-Hydroxydopamine
Kostrzewa, R. M., & Jacobowitz, D. M. (1974) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06677-3 · Cited by 817
Catecholamines: Basic and Clinical Frontiers
(1979) · Elsevier eBooks · doi:10.1016/c2013-1-15197-0 · Cited by 728
EFFECTS OF 6‐HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN
Uretsky, N. J., & Iversen, L. L. (1970) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1970.tb02210.x · Cited by 653
6-Hydroxydopamine and catecholamine neurons
Malmfors, T., Thoenen, H., & Co, F. H.-L. R. (1971) · North-Holland eBooks · Cited by 634
Cited by
Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.1 · Cited by 1,072
“The substantial and irreversible loss of catecholamines by metabolism, following leakage of the amines from storage vesicles into the cytoplasm, might seem inconsistent with cellular economy.”
BackgroundThe oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Oxidative damage in the central nervous system: protection by melatonin
Reiter, R. J. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00052-5 · Cited by 838
Berman, S. B., & Hastings, T. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731127.x · Cited by 664
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
Self-citationA cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
Liu, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90425-c · Cited by 594
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse
Itier, J.-M. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg239 · Cited by 508
Cytotoxic and genotoxic potential of dopamine
Stokes, A. H., Hastings, T. G., & Vrana, K. E. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990315)55:6<659::aid-jnr1>3.0.co;2-c · Cited by 469
LEE, F. J. S., LIU, F., PRISTUPA, Z. B., & NIZNIK, H. B. (2001) · The FASEB Journal · doi:10.1096/fj.00-0334com · Cited by 455
LaVoie, M. J., & Hastings, T. G. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-04-01484.1999 · Cited by 447
An introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382
Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370
Self-citationThe Role of Monoamine Metabolism in Oxidative Glutamate Toxicity
Maher, P., & Davis, J. B. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-20-06394.1996 · Cited by 336
The effect of deprenyl and levodopa on the progression of Parkinson's disease
Olanow, C. W., Hauser, R. A., Gauguster, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., & Esterlitz, J. (1995) · Annals of Neurology · doi:10.1002/ana.410380512 · Cited by 334
Differential expression of two vesicular monoamine transporters
Peter, D., Liu, Y., Sternini, C., de Giorgio, R., Brecha, N., & Edwards, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-09-06179.1995 · Cited by 333
Dopamine Induces Apoptosis through an Oxidation-involved SAPK/JNK Activation Pathway
Luo, Y., Umegaki, H., Wang, X., Abe, R., & Roth, G. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.6.3756 · Cited by 310
The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation
Lotharius, J., & O'Malley, K. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005385200 · Cited by 306
THE ROLE OF VESICULAR TRANSPORT PROTEINS IN SYNAPTIC TRANSMISSION AND NEURAL DEGENERATION
Liu, Y., & Edwards, R. H. (1997) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.20.1.125 · Cited by 296
Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 295
Intraneuronal dopamine-quinone synthesis: a review
Sulzer, D., & Zecca, L. (1999) · Neurotoxicity Research · doi:10.1007/bf03033289 · Cited by 284
The Effects of Methamphetamine on the Production of Free Radicals and Oxidative Stress
Yamamoto, B. K., & Zhu, W. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37769-9 · Cited by 281
Mitochondria and degenerative disorders
Orth, M., & Schapira, A. H. V. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1425 · Cited by 280
Oxidative Damage and Schizophrenia: An Overview of the Evidence and Its Therapeutic Implications
Yao, J. K., Reddy, R. D., & van Kammen, D. P. (2001) · CNS Drugs · doi:10.2165/00023210-200115040-00004 · Cited by 280
The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease
Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218
Lam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184
Ding, Y. M., Jaumotte, J. D., Signore, A. P., & Zigmond, M. J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02415.x · Cited by 137
Sadasivan, S., Pond, B. B., Pani, A. K., Qu, C., Jiao, Y., & Smeyne, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033693 · Cited by 102
Metadata
- Authors
- Michel, P. P., & Hefti, F.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 1990-08
- Volume
- 26
- Issue
- 4
- Pages
- 428-435
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2105551817
- Cited by
- 338
- References
- 30
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.